BCLS Fund III Investments, LP filed Amendment No. 3 to a Schedule 13G with the SEC on November 16, 2026, disclosing its beneficial ownership of common stock in Heartflow, Inc. as of September 30, 2026.
Key Highlights
- Reporting person: BCLS Fund III Investments, LP, a Delaware limited partnership affiliated with Bain Capital Life Sciences.
- Shares held: 4,448,158 shares of Heartflow, Inc. Common Stock, $0.001 par value per share.
- Ownership percentage: 5.06% of the outstanding Common Stock, based on 87,887,561 shares outstanding as of October 31, 2026.
- Voting and dispositive power: The reporting person holds zero sole voting or dispositive power; all 4,448,158 shares are held with shared voting and shared dispositive power.
- Event date: The date of the event requiring this filing is September 30, 2026.
- Share count basis: The outstanding share figure was drawn from Heartflow's Quarterly Report for the quarter ended September 30, 2026, filed with the SEC on November 12, 2026.
BCLS Fund III Investments Reports Shared Ownership in Heartflow Common Stock
According to the filing, BCLS Fund III Investments, LP held 4,448,158 shares of Heartflow, Inc. common stock as of the close of business on September 30, 2026, representing approximately 5.1% of the outstanding common stock, as stated in Item 4(a). The percentage shown in the cover page of the Schedule 13G is listed as 5.06%, calculated using 87,887,561 shares outstanding as of October 31, 2026, as reported by the issuer in its most recent quarterly filing.
The filing describes a chain of affiliated entities under the Bain Capital Life Sciences umbrella. Bain Capital Life Sciences Investors, LLC serves as the manager of Bain Capital Life Sciences III General Partner, LLC, which is the general partner of Bain Capital Life Sciences Fund III, L.P. That fund is the managing member of BCLS Fund III Investments GP, LLC, which in turn is the general partner of the reporting person, BCLS Fund III Investments, LP. The filing notes that as a result of this structure, Bain Capital Life Sciences Investors, LLC "may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Person." The principal business address for all Bain Capital Life Sciences Entities listed in the filing is 200 Clarendon Street, Boston, Massachusetts 02116.
Heartflow, Inc. is identified in the filing as the issuer, with its principal executive offices located at 135 Main Street, Suite 1000, San Francisco, California 94105. The common stock carries a CUSIP number of 42238D107. The filing was signed by Nicholas Downing, Partner of Bain Capital Life Sciences Investors, LLC, on November 16, 2026. This is the third amendment to the Schedule 13G originally filed by the reporting person with respect to Heartflow common stock.
What Was Disclosed
BCLS Fund III Investments, LP disclosed beneficial ownership of 4,448,158 shares of Heartflow, Inc. common stock, representing 5.06% of shares outstanding as of September 30, 2026, with all voting and dispositive power held on a shared basis through affiliated Bain Capital Life Sciences entities.




Please wait processing your request...